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Abstract. Neurotransmitter system dysfunction and synapse loss have been recognized as hallmarks of Alzheimer’s disease (AD).
Our hypothesis is that specific neurochemical populations of neurons might be more vulnerable to degeneration in AD due to
particular deficits in synaptic plasticity. We have studied, in postmortem brain tissue, the relationship between levels of synaptic
markers (NCAM and BDNF), neurochemical measurements (cholinacetyltransferase activity, serotonin, dopamine, GABA, and
glutamate levels), and clinical data (cognitive status measured as MMSE score). NCAM levels in frontal and temporal cortex
from AD patients were significantly lower than control patients. Interestingly, these reductions in NCAM levels were associated
to an ApoE4 genotype. Levels of BDNF were also significantly reduced in both frontal and temporal regions in AD patients. The
ratio between plasticity markers and neurochemical measurements was used to study which of the neurochemical populations
was particularly associated to plasticity changes. In both the frontal and temporal cortex, there was a significant reduction in
the ChAT/NCAM ratio in AD samples compared to controls. None of the ratios to BDNF were different between control and
AD samples. Furthermore, Pearson’s product moment showed a significant positive correlation between MMSE score and the
ChAT/NCAM ratio in frontal cortex (n = 19; r = 0.526*; p = 0.037) as well as in temporal cortex (n = 19; r = 0.601*; p =
0.018) in AD patients. Altogether, these data suggest a potential involvement of NCAM expressing neurons in the cognitive
deficits in AD.
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INTRODUCTION
Alzheimer’s disease (AD) is a chronic progressive
neurodegenerative disorder characterized by a gradu-
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al loss of cognitive function and is the major form of
dementia affecting the elderly. Since the first reports
of loss of basal forebrain acetylcholine-synthesizing
neurons and associated neurochemical perturbation of
presynaptic cholinergic markers [1,2], neurotransmit-
ter system dysfunction and synapse loss have been rec-
ognized as hallmarks of AD along with senile plaques
and neurofibrillary tangles [3–7]. The cholinergic dys-
function, together with glutamatergic deficits, is con-
sidered that may trigger, in part, some of aspects of
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cognitive disturbance in AD [8–11]. Deficiencies in
central serotonergic [12–15] and perhaps dopaminer-
gic [16], but see also [17,18] neural transmission may
also play a critical role in some of the clinical mani-
festations of AD. Significant reductions in γ-amino bu-
tyric acid (GABA) levels have also been described in
cases of AD [19].
Our hypothesis is that specific neurochemical popu-
lations of neurons might be more vulnerable to degen-
eration in AD due to deficits in synaptic plasticity. One
class of molecules that may contribute to plasticity in
the central nervous system (CNS) are glycoproteins in-
volved in the adhesion of neural cells. These adhesion
glycoproteins are believed to regulate the stabilization
of synaptic junctions, neurite outgrowth, wound repair,
functional plasticity, and control release of neurotrans-
mitter. The neural cell adhesion molecule (NCAM) is
a part of a family of cell-surface glycoproteins that
plays key roles in normal brain development, including
axonal/dendritic growth and branching, and synaptic
plasticity [20–23]. Through alternative splicing, three
major isoforms of NCAM are generated: NCAM120,
−140, and −180. NCAM can be also modified by the
addition of α-2,8-polysialic acid (PSA-NCAM). At the
systems level, NCAMs have been implicated as critical
components in the induction of long-term potentiation
(LTP) and in memory formation [20,21] NCAMs have
been shown to play critical roles in ontogenetic devel-
opment and are thus potential candidates in expression
of age-related pathology, particularly in AD [24,25].
The aim of the present work was to study if a partic-
ular neurochemical deficit is associated to NCAM al-
terations in AD. We have checked the proportion of the
amount of NCAM relative to the amount of each of the
neurotransmitters studied [26]. For comparative pur-
poses, we have studied another classically used mark-
er of plasticity, neurotrophin brain-derived neurotroph-
ic factor (BDNF), an activity-dependent secreted pro-
tein that is critical to organization of neuronal networks
and synaptic plasticity (see recent review [27]). Re-
duced levels of BDNF have been documented in studies
of postmortem brain tissue from AD patients [28–30].
Moreover, BDNF mRNA levels were decreased in AD
in the nucleus basalis of Meynert, the main source of
cholinergic innervation to the cerebral cortex [31,32].
We have used clinical data and postmortem brains
(frontal and temporal cortex), collected as part of a
prospective community-based study of dementia [33],
to study the relationship between levels of synaptic
markers (BDNF and NCAM), neurochemical mea-




Number of patients 16 19
Gender (man/woman) 9/7 11/8
ApoE (2,3/4) −/16 12/7
Braak stage 1–2 5–6
Age (years) 78.75 ± 2.67 81.06 ± 1.60
range 53–99 64–89
Postmortem delay (h) 39.28 ± 5.40 48.63 ± 6.30
pH 6.28 ± 0.16 6.44 ± 0.10
Values are mean ± S.E.M. pH, standard chemical symbol, neg-
ative log of hydrogen ion concentration; S.E.M, Standard error
of the mean. Values are mean ± S.E.M. ApoE4 = AD patients
lacking one or two copies of the ApoE4 allele. There were no
significant differences between age, postmortem delay, or brain
pH in either control patients or those with dementia (Student
t-test, p > 0.05).
dopamine, GABA, and glutamate levels) and clinical
data (cognitive status). On the other hand, inheritance
of the ε4 allele of the apolipoprotein E gene (ApoE4)
is a major risk factor for the development of AD. Al-
though the association between ApoE4 and AD is well
documented, the mechanism by which ApoE exerts
an isoform-specific effect on neurons in disease is un-
known. Therefore, we thought of interest to check the
influence of expressing the ApoE allele on synaptic
changes in AD. Based on our data, we propose that
there is an association between cholinergic alterations,
NCAM expression, and ApoE genotype, which might
be related to the cognitive deficits in AD.
MATERIAL AND METHODS
Patients and assessment of behavior
A total of 35 individuals from the Thomas Willis
Oxford Brain Collection were included in the study,
19 patients with clinical diagnosis of dementia, and 16
elderly normal controls matched for age, gender, post-
mortem delay, and brain pH (Table 1). Those patients
with dementia were an autopsied subset of subjects in-
cluded in a prospective study of behavioral changes in
clinically diagnosed as demented patients [33]. Drug
histories were recorded for all patients, and none of
the patients with AD received cholinomimetics. At en-
try to the study assessment, diagnoses were made us-
ing Cambridge Mental Disorders of the Elderly Ex-
amination (CAMDEX) [34], DMS-III-R criteria [35],
and NINCDS-ADRA criteria [36]. Cognitive status
was assessed using the Mini-Mental State Examina-
tion (MMSE) [37]. Severity of dementia was deter-
B. Aisa et al. / NCAM, Cholinergic System, and Alzheimer’s Disease 661
mined according to MMSE score at last interview be-
fore death. All tissues from control patients were ex-
amined by a pathologist and were confirmed to be free
of gross neuropathology; clinical information indicated
no gross neurological or psychiatric disorder.
Tissue samples and neuropathology
For all subjects, informed consent had been obtained
from relatives before the removal of brain tissue at death
and subsequent use of the material for research. The
study had Local Ethics Committees’ approval. Selec-
tion of subjects for the study was based on tissue avail-
ability, not gender, age, or disease severity. At autop-
sy, brains were removed and blocks corresponding to
frontal (Brodmann area 10, BA10) and temporal (Brod-
mann area 20, BA20) cortex and were stored at −80◦C
until processing. All patients were found to meet CER-
AD criteria [4] for a diagnosis of AD, and all brains
were Braak stage 5 or 6 as assessed by a neuropatholo-
gist. To partially mitigate the possible effects of cause
of death on neurochemical determinations, brain pH
was measured with deionised water [38] as an index
of acidosis associated with terminal coma (Table 1).
Brain pH is used as an indication of tissue quality in
postmortem research, with pH > 6.1 considered ac-
ceptable [39]. All subsequent analyses were performed
blind to clinical information.
Cholinacetyltransferase (ChAT) activity
ChAT activity was performed as described [14].
Frontal or temporal cortex was homogenized in 50 vol.
of 0.87 mM EDTA containing 0.1% Triton X-100
(pH 7.0). Duplicated samples of 10 µl from ho-
mogenates were used in the assay. The reaction mixture
comprised the following: 87 nM EDTA (pH 7.4), 0.5 M
NaH2PO4 (pH 7.4), 40 mM choline chloride 3 M NaCl,
2 nM eserine salicylate, and 2 mM [14C]-actetyl CoA
(Amersham, UK). Samples were incubated at 37◦C for
30 min. Water was used as sample blanks. The reaction
was terminated by adding 100 µl of cold water. The
acetylcholine product was separated using Kalignost
solution: 0.5% cold di-sodiumtetraphenylborate in 15–
85% acetonitrile-toluene. The supernatant was then
transferred to scintillation cocktail (Ecoscint TM) and
radioactivity was measured. Results were expressed as
percentage of control values.
Serotonin, dopamine, glutamate, and GABA
measurements
Concentrations of different neurotransmitters were
determined by high performance liquid chromatog-
raphy (HPLC) with electrochemical detection (Wa-
ters Spheribor S10 0DS2 4,6 × 150 mm), including
precolumn derivatization with o-phthaldehyde and β-
mercapthoethanol [40] for GABA and glutamate deter-
minations.
As previously described [14], for serotonin (5-HT)
and dopamine (DA) determinations, tissue was homog-
enized in 20 v of extraction mixture (0.4 M percloric
acid; 1 mM EDTA; 0.1% metabisulphitic acid). Ho-
mogenates were centrifugated 32,500 g for 20 min.
The mobile phase consisted of 80:16 (v/v) mixture of
buffer (KH2PO4·2H2O 0.1 M, citric acid 0.1 M, ED-
TA 1 mM and octanosulphonic acid 0.74 mM; pH =
3). 5-HT content was calculated by comparing with a
1 ng standard. The limit of detection was 1 pg/10 µl.
DA content was calculated by comparing with a 0.5 ng
standard. The limit of detection was 1 pg/10 µl.
For GABA or glutamate determinations, tissue was
homogenized in 200 v of 0.1 M di-sodiumtetraborate
(pH 9.1). Homogenates were centrifuged at 32,500 g
for 20 min. The mobile phase consisted of 72:28
(v/v) mixture of buffer (NaH2PO4 0.1 M, pH = 5.5)
and methanol; the mixture was filtered and degassed
through a 0.22µm nitrocellulose membrane (Millipore,
UK). Glutamate and GABA content were calculated by
comparing with a 2 ng standard. The limit of detec-
tion was 20 pg/10 µl for glutamate and 50 pg/10 µl for
GABA content.
Quantification of total levels of BDNF
The samples were processed with a commercially
available sandwich enzyme-linked immunosorbent as-
say (ELISA) measuring BDNF protein (BDNF Emax
immunoassay system, Promega Co, USA). All samples
and standards were prepared in duplicate. Incubation
and washing were conducted according to the manufac-
turer’s instructions with reagents from the kit, at room
temperature, sealed, and on a shaker. The optical den-
sity of the wells was analyzed in a Bio-Rad Microplate
Reader at 450 nm. A standard curve was generated
from the serial BDNF standard dilutions, and BDNF
protein concentrations in the samples were extrapolat-
ed directly from the standard curve. BDNF levels were
expressed as pg/mL.
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Quantification of total levels of NCAM
Crude synaptosomal pellets were obtained according
to a protocol from [41]. Hippocampal tissue was ho-
mogenized in 10 vol of ice-cold sucrose (0.32 M) and
HEPES (5 mM) buffer that contained a cocktail of pro-
tease inhibitors (Complete TM, Boehringer Mannheim,
UK) and centrifuged at 1000 g for 5 min. The su-
pernatant was then centrifuged again at 15,000 g for
15 min, and the pellet resuspended in Krebs buffer.
Protein concentration for each sample was estimated
as previous [42]. NCAM levels were quantified ac-
cording to a previously described protocol [25]. Flat
bottom 96-well microplates were allowed to adsorb a
coating solution (Na2CO3 0.1 M/ NaHCO3, 0.1 M)
for 2 h at room temperature. The solution was re-
moved and 50 µl of pellet samples added at a concen-
tration of 10 mg/ml to each well of polystyrene flat-
bottom ELISA plates. Plates were incubated overnight
at 4◦C and then washed three times with 1 M phos-
phate buffered saline (PBS) containing 0.05% Tween
20, pH 7.4. Additional binding sites were blocked with
bovine serum albumin (BSA) (3%) for 2 h at room tem-
perature. Wells were incubated with 50 µl aliquots of
primary antibody Ab5032 (1:15,000 TBST; Chemicon)
for 20–24 h at 4◦C and subsequently, 50 µl aliquots of
antirabbit IgG peroxidase conjugate antibody (1:500;
Sigma, UK) were added for a 2 h incubation peri-
od. TMB (Promega) was used as a chromogenic sub-
strate. The reaction was terminated by the addition of
1 N hydrochloric acid. Absorbancies were measured at
450 nm using an automatic ELISA microplate reader.
Results were expressed as absorbance.
ApoE genotyping
ApoE genotyping was performed with DNA extract-
ed from tissues according to [43].
Statistical analysis
Data were analyzed by SPSS for Windows, release
15.0. Normality was checked by Shapiro-Wilks’s test
(p > 0.05). Student’s t-test was used in comparisons
between controls and AD samples. The effects of de-
mographic factors (age, postmortem delay, and brain
pH) on neurochemical variables, intercorrelation be-
tween neurochemical variables or relationships be-
tween MMSE score and neurochemical measures were
determined by Pearson’s or Spearman’s correlation co-
efficients, according to the normality of variables.
RESULTS
There were no significant differences in age, post-
mortem delay, or brain pH between the control and AD
groups. A summary of demographic details of controls
and AD patients is shown in Table 1. In addition, no
significant correlations between age, postmortem de-
lay, or brain pH and any of the neurochemical variables
studied in either controls or AD (p > 0.05) were found.
However, in a conservative analysis of data, they were
included as covariates in order to avoid age or post-
mortem delay interferences in subsequent analysis.
Neurochemical characterization of samples
As shown in Table 2, ChAT activity in AD was re-
duced by 70% (BA10) or 60% (BA20) in comparison
to control. Significant decreases in 5-HT, DA, and GA-
BA levels were also found both in BA10 or BA20 sam-
ples from AD patients. Glutamate content in AD brains
was not significantly different from that observed in
controls.
Plasticity markers in Alzheimer’s disease
NCAM levels in frontal and temporal cortex from
AD patients were significantly lower than control pa-
tients (Student’s t-test; p < 0.05). Reductions reached
22% (1.00± 0.10 vs. 0.79± 0.04 pg/ml) in BA10 and
21.7% (0.51 ± 0.04 vs. 0.40 ± 0.02 pg/ml) in BA20
when compared to control values (Fig. 1A). None of
the controls showed an ApoE4 genotype. Interestingly,
these reductions in NCAM levels in AD were associat-
ed to an ApoE4 genotype: significant reductions were
found in patients showing an ApoE 4 genotype (con-
trol vs. AD, in pg/ml, BA10: 1.00 ± 0.10 vs. 0.71 ±
0.07; BA20: 0.51 ± 0.04 vs. 0.36 ± 0.02), while no
differences in NCAM levels were found in AD patients
lacking one or two copies of the ApoE4 allele (control
vs. AD, in pg/ml, BA10: 1.00 ± 0.10 vs. 0.93 ± 0.05;
BA20: 0.51 ± 0.04 vs. 0.48 ± 0.03).
BDNF levels were significantly reduced (Student’s
t-test; p < 0.05) in both frontal and temporal re-
gions in AD patients. BDNF reductions reached 40%
(2123.21± 223.57 vs. 1277.6044± 251.24 pg/ml) and
47% (2603.35 ± 364.53 vs. 1439.33 ± 163.18 pg/ml)
in BA10 and BA20 regions respectively (Fig. 1B). No
effects of ApoE genotype on BDNF reductions in AD
patients were found.
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Table 2
Neurochemical measurements and their ratio to plasticity markers in the frontal (BA10) and temporal (BA20) cortex
of controls and Alzheimer’s disease (AD) patients
Frontal cortex (BA 10) Temporal cortex (BA20)
Control AD Control AD
ChAT 100.00 ±9.82 27.68 ± 3.55∗ 100.00 ± 7.34 38.82 ± 7.88∗
ChAT/NCAM 108.15 ± 12.52 41.28 ± 7.64∗ 214.17 ± 16.79 89.08 ± 21.12∗
ChAT/BDNF 0.06 ± 0.12 0.05 ± 0.02 0.05 ± 0.02 0.04± 0.01
5-HT 42.95 ± 3.25 25.41 ± 1.99∗ 44.50 ± 2.86 23.95 ± 1.39∗
5-HT/NCAM 53.66 ± 7.96 37.75 ± 5.82 92.92 ± 9.37 62.62 ± 3.91∗
5-HT/BDNF 0.03 ± 0.05 0.05 ± 0.02 0.02 ± 0.01 0.02± 0.01
DA 91.70 ± 15.51 43.55 ± 5.84∗ 109.35 ± 16.77 45.45 ± 7.07∗
DA/NCAM 106.63 ± 27.05 56.42 ± 9.66 187.32 ± 37.03 110.56 ± 19.63
DA/BDNF 0.04 ± 0.01 0.09 ± 0.03 2.79 ± 0.55 4.63± 0.55
GABA 704.39 ± 63.41 555.33 ± 31.97∗ 579.94 ± 31.72 457.44 ± 31.70∗
GABA/NCAM 901.06 ± 144.66 791.44 ± 100.67 1237.57 ± 129.40 1256.17 ± 108.19
GABA/BDNF 0.47 ± 0.11 0.70 ± 0.23 0.31 ± 0.05 0.45± 0.09
Glutamate 5767.11 ± 411.73 5297.91 ± 322.52 4967.06 ± 233.81 4986.11 ± 357.35
Glutamate/NCAM 7117.01 ± 1032.51 7385.94 ± 1013.41 10150.54 ± 825.25 12990.99 ± 1105.91
Glutamate/BDNF 3.67 ± 0.75 11.48 ± 4.15 0.05 ± 0.01 0.04± 0.01
Values are mean± S.E.M from control (n = 16) and Alzheimer’s disease patients (n = 19). ChAT activity is expressed
as percentage of activity relative to control. 5-HT, dopamine (DA), GABA and glutamate levels are expressed as pg/mg
of tissue. ∗Significantly lower than Control, Student t-test, p < 0.01 or p < 0.001.
A)
B)
Fig. 1. Reductions in plasticity markers in the frontal (BA10) and temporal (BA20) cortex of Alzheimer’s disease (AD) patients. A) NCAM
levels, expressed as absorbance; B) BDNF levels. N = 16–19; ∗ p < 0.05 vs. control, Student’s t-test.
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Fig. 2. Significant correlations (Pearson’s correlation coefficient) between ChAT/NCAM ratio and MMSE score in the frontal (BA10, n = 19,
r = 0.526, p = 0.037) and temporal cortex (BA20, n = 19, r = 0.601, p = 0.018) in Alzheimer’s disease (AD) patients.
Relationship between plasticity markers and
neurochemical measurements
The ratio between plasticity markers and neurochem-
ical measurements was used to study which of the neu-
rochemical populations was particularly associated to
plasticity changes. In the frontal cortex, there was a
significant reduction (Student’s t-test; p < 0.05 or p <
0.01) in ChAT/NCAM and 5-HT/NCAM ratios in AD
samples compared to controls. None of the ratios to
BDNF were different between control and AD samples.
In the temporal cortex, only the ratio ChAT/NCAM was
significantly lower in AD samples. All these results are
shown in Table 2.
Correlations with cognitive status
In AD patients mean MMSE score before death was
5 ± 1 (range varies between 0 and 21).
ChAT activity correlated to MMSE score both in
the frontal (Pearson’s product moment, n = 19; r =
0.524*; p = 0.018) and temporal cortex (n = 19; r =
0.759*; p < 0.001). NCAM levels did not correlate
to MMSE score (n = 19; r = 0.150; p = 0.564 for
the frontal cortex, n = 19; r = 0.142; p = 0.599 for
the temporal cortex). Statistical analysis showed a sig-
nificant positive correlation between MMSE score and
the ChAT/NCAM ratio in frontal cortex (n = 19; r =
0.526*; p = 0.037) as well as in temporal cortex (n =
19; r = 0.601*; p = 0.018) in AD patients (Fig. 2).
When split by ApoE genotype, these correlations were
associated to an ApoE4 genotype (n = 7; r = 0.796*;
p = 0.032 for the frontal cortex, n = 7; r = 0.526*;
p = 0.037 for the temporal cortex), while no corre-
lations were found in AD patients lacking the ApoE4
genotype (n = 12; r = 0.211; p = 0.789 for the frontal
cortex, n = 12; r = 0.938; p = 0.062 for the temporal
cortex). BDNF levels or BDNF ratios did not correlate
to MMSE score in either cortical region. No other cor-
relation related to other neurotransmitter systems has
been found.
DISCUSSION
In the present work, we have found that: 1) NCAM
levels are decreased in the frontal and temporal cortex
of AD patients, and these decreases are associated with
an ApoE4 genotype; and 2) the ratio of ChAT/NCAM is
significantly reduced in the frontal and temporal cortex
of AD patients. Furthermore, the ChAT/NCAM ratio,
both in the frontal and temporal cortex, and particularly
in ApoE4 carriers, was correlated to cognitive deficits
in AD. Altogether, these data suggest a potential in-
teraction between the cholinergic system and NCAM
expressing neurons, which functionally correlates to
cognitive deficits.
Synaptic loss is the major neurobiological substrate
of cognitive dysfunction in AD. Synaptic failure is an
early event in the pathogenesis that is clearly detectable
already in patients with mild cognitive impairment, a
prodromal state of AD (reviewed by [44]). It progress-
es during the course of AD and in most early stages in-
volves mechanisms of compensation (synaptic remod-
eling or synaptogenesis) before reaching a stage of
decompensated function (degeneration) [45,46]. This
synaptic degeneration in AD leads to important neuro-
chemical alterations in the brains of AD patients and
different neurotransmitter systems have been shown to
be altered in AD (see review [47]). The neurochemical
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correlates of clinical dysfunctions in AD are not yet
fully understood [48], but changes in neurochemistry
could be the key to understanding the pathogenesis of
cognitive deficits. Among them, the classical hallmark
of AD is the disruption of basal forebrain choliner-
gic pathways and consequent cholinergic denervation
of the neocortex and hippocampus. This cholinergic
dysfunction has been largely related to disturbance of
attentional aspects of cognition [10,11,49].
In experimental studies, NCAM expression seems
to be important, and perhaps essential, for long-term
information storage [50,51]. For example, administra-
tion of NCAM antibodies impaired spatial learning and
passive avoidance learning in rats [52]. Administration
of a synthetic peptide, which mimics NCAM activa-
tion, enhanced spatial memory [53]. Furthermore, null
mutation of the NCAM gene in mice leads to impaired
spatial learning and memory [54,55]. At a molecular
level, expression of LTP was suppressed by the admin-
istration of antibodies against NCAM or synthetic pep-
tides interfering with NCAM activity [56–58]. A re-
cent study, [59] postulated that NCAM was upregulated
during the early stages of spatial water maze learning,
supporting the implication of this NCAM regulatory
mechanism on spatial learning and memory.
No changes [60] or increased [61,45] levels of
NCAM have been reported in the hippocampus of AD
patients, but this increase has been related to increased
neurogenesis, and may be indicative of an attempt of the
brain to restore structure and function or to compensate
for the damage caused by the disease. Soluble forms of
NCAM are increased in the cerebrospinal fluid of both
AD and Parkinson disease patients, but these increases
seem to be related to aging and neurodegeneration and
not to dementia as such [62]. In the serum samples,
only levels of low molecular weight forms of NCAM
correlated to severity of dementia [63]. When focusing
on the cortex, according to our results, decreased levels
of NCAM have been found in the frontal cortex of AD
patients [64], probably reflecting synaptic loss in the
illness. An interesting finding of the present work is
the association of NCAM decreases in AD to an ApoE4
genotype. Inheritance of the ε4 allele of the ApoE gene
(ApoE4) is a major risk factor for the development of
AD. Although the association between ApoE4 and AD
is well documented, the mechanism by which ApoE
exerts an isoform-specific effect on neurons in disease
is little known. On top of already proposed mecha-
nisms, we suggest that the presence of the ApoE4 al-
lele might differential affect NCAM-expressing neu-
rons [65], since neither BDNF levels (present data) nor
synaptophysin or PSD95 levels [66] were affected by
the ApoE4 genotype. However, it has to be noted that
none of the controls showed an ApoE4 genotype. The
lack of information of the effect of ApoE4 in controls
prevents us to discriminate if the NCAM reduction is
due to AD in ApoE4 carriers or just to the effect of the
E4 isoform in general. It is known that ApoE4 car-
riers (with and without neurodegenerative disorders)
have less synaptic plasticity and regeneration processes
than E3 carriers [67]. On the other hand, the enhanced
synaptic regenerative processes in non-carriers of the
ApoE4 allele could lead to an enhanced NCAM synthe-
sis/expression and therefore, could be masking NCAM
decreases associated to AD.
As expected, considering that most of the patients
in this study were severe AD (MMSE score equal or
less than 10), decreases in most of the neurochemi-
cal/plasticity markers studied have been found. The ra-
tio between plasticity markers and neurochemical mea-
surements was used to study which of the neurochemi-
cal populations was associated with changes in NCAM
and/or BDNF. Our results seem to suggest that there
is a selective loss of cholinergic neurons expressing
NCAM in AD. As an alternative explanation, it can
be also argued that the ratio ChAT/NCAM decreases
because decreases in NCAM levels in AD are smaller
that decreases in ChAT activity. In any case, this re-
lationship between ChAT-NCAM seems to be related
to cognitive alterations in AD, as suggested by present
data on the correlation between ChAT/NCAM ratio and
MMSE score. It is noticeable that considering the com-
ponents of the ratio, only ChAT levels correlated per
se with cognitive status. Therefore it seems that loss of
cholinergic neurons expressing NCAM, and particular-
ly in ApoE4 carriers, has driven the statistical correla-
tion. It has to be considered that even though the func-
tional link between cholinergic neurons and NCAM-
expressing neurons has been described in the periphery,
little is known regarding co-expression of cholinergic-
NCAM neurons in the CNS. In light of the present
data, future studies, e.g., using immunohistochemical
methods, could confirm our hypothesis of a selective
loss of ChAT labeling in NCAM expressing neurons.
As to the mechanism responsible for the association
of ChAT-NCAM, it is of note that in the same cohort
of postmortem samples used for the present study, the
presence of the ApoE4 allele selectively correlated to
loss of ChAT activity [68].
In addition, for comparative purposes, we have stud-
ied BDNF, another classically used marker of plastici-
ty. It is widely accepted that alterations of BDNF levels
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or its receptors occur during normal aging and AD (see
review, [32]). The lack of significant changes in the ra-
tio to BDNF in any of the neurochemical markers used
seem to support our hypothesis that synaptic changes
in cholinergic neurons seem to be specifically related to
NCAM expressing terminals. A note of caution should
be mentioned at this point, pointing to the interest for
future studies of measuring NCAM level, as well as
the rest of the molecules implicated in cognition, in
AD in early stages, when cognitive impairment exists
but the brain is less affected by numerous pathological
changes.
The present data support the notion that treatments
to increase or mimic the function of NCAM might
improve neuronal connectivity and cognition, perhaps
through a cholinergic-mediated mechanism. NCAM-
mimicking peptides are being developed for their po-
tential efficacy [69,70], although the therapeutic effica-
cy of these NCAM-peptide mimetics remains to be test-
ed. In a recent study the ability of C3d,a NCAM mimet-
ic peptide, to promote ChAT activity in septal choliner-
gic neurons was reported [71]. On the other hand, treat-
ment with cholinesterase inhibitors, which improve
cholinergic function, increases PSA-NCAM in the hip-
pocampus [72]. Furthermore, these enhancements cor-
related directly with improved spatial learning ability,
suggesting that an improved memory-associated synap-
tic plasticity may be the fundamental mechanism un-
derlying the disease modifying action of this kind of
drugs [73]. In this sense, pharmacological manipula-
tion of the cholinergic system may improve not only
cognitive function but also plasticity disturbances in
dementia.
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